Brief: Aprea Therapeutics- On June 29 Co Got Deficiency Letter From Nasdaq Regarding Minimum Bid Price Requirement
01/07/2022 22:23
July 1 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS- ON JUNE 29 CO GOT DEFICIENCY LETTER
FROM
NASDAQ REGARDING MINIMUM BID PRICE REQUIREMENT
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing